Guardant Health (NASDAQ:GH) Insider John Saia Sells 20,000 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) insider John Saia sold 20,000 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total value of $2,130,200.00. Following the completion of the sale, the insider directly owned 45,950 shares in the company, valued at approximately $4,894,134.50. The trade was a 30.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health Stock Up 0.8%

Shares of GH stock opened at $118.95 on Friday. The stock has a market cap of $15.77 billion, a price-to-earnings ratio of -35.09 and a beta of 1.48. The business’s fifty day moving average is $91.15 and its 200 day moving average is $98.94. Guardant Health, Inc. has a twelve month low of $36.36 and a twelve month high of $121.01.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $281.27 million during the quarter, compared to the consensus estimate of $269.74 million. During the same quarter last year, the firm posted ($0.62) earnings per share. The firm’s revenue for the quarter was up 39.4% compared to the same quarter last year. Equities research analysts expect that Guardant Health, Inc. will post -2.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GH. Raymond James Financial reaffirmed an “outperform” rating and set a $129.00 price target on shares of Guardant Health in a report on Monday, February 23rd. Citigroup increased their target price on Guardant Health from $135.00 to $150.00 and gave the company a “buy” rating in a report on Friday, February 20th. TD Cowen reissued a “buy” rating on shares of Guardant Health in a report on Thursday. Barclays increased their target price on Guardant Health from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, Guggenheim increased their target price on Guardant Health from $115.00 to $135.00 and gave the company a “buy” rating in a report on Monday, January 26th. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $129.00.

Institutional Trading of Guardant Health

Several institutional investors have recently made changes to their positions in GH. Emerald Advisers LLC grew its holdings in Guardant Health by 24.8% during the 3rd quarter. Emerald Advisers LLC now owns 873,203 shares of the company’s stock valued at $54,558,000 after buying an additional 173,281 shares in the last quarter. Knights of Columbus Asset Advisors LLC bought a new stake in shares of Guardant Health in the 3rd quarter valued at approximately $1,554,000. Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in shares of Guardant Health by 54.4% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 301,449 shares of the company’s stock valued at $18,835,000 after purchasing an additional 106,263 shares during the last quarter. Erste Asset Management GmbH lifted its stake in shares of Guardant Health by 10.4% in the 3rd quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock valued at $43,716,000 after purchasing an additional 66,617 shares during the last quarter. Finally, Segall Bryant & Hamill LLC lifted its stake in shares of Guardant Health by 57.8% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock valued at $19,066,000 after purchasing an additional 111,822 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.